Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia

Vahid Afshar-Kharghan, José A. López, Leigh A. Gray, Arnoldo Padilla, Gautam Borthakur, Stacy C. Roberts, Rajiv K. Pruthi, Ayalew Tefferi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Patients with polycythemia vera and essential thrombocythemia are at risk for thrombotic and bleeding complications. Currently, no diagnostic test can predict thrombohemorrhagic complications. In a prospective study of 86 patients with polycythemia vera (43 patients) or essential thrombocythemia (43 patients), we examined the possible role of polymorphisms of platelet adhesion receptors [glycoprotein (GP) Ibα, GPIa, GPIIIa) and clotting factor II (prothrombin's G20210A mutation) and clotting factor V (Leiden mutation) in determining the risk of thrombotic or bleeding complications. Except for an association between vasomotor symptoms and prothrombin mutation (P < 0.001), no significant correlation between polymorphism of clotting factors and thrombohemorrhagic complications was identified. When the entire patient cohort was considered, the polymorphisms of platelet adhesion receptors were not associated with the risk for thrombotic or bleeding complications. However, among patients with polycythemia vera, the presence of the PIA2 allele of GPIIIa was associated with an increased risk of arterial thrombosis. In view of previous studies linking the presence of the PIA2 allele of GPIIIa to a higher risk for coronary artery thrombosis, our data have physiologic relevance. However, they need to be confirmed in a larger study.

Original languageEnglish (US)
Pages (from-to)21-24
Number of pages4
JournalBlood Coagulation and Fibrinolysis
Volume15
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Hemostatics
Integrin beta3
Blood Coagulation Factors
Prothrombin
Genes
Hemorrhage
Mutation
Integrin alpha2
Blood Platelets
Alleles
Platelet Glycoprotein GPIb-IX Complex
Coronary Thrombosis
Routine Diagnostic Tests
Coronary Vessels
Thrombosis
Prospective Studies

Keywords

  • Essential thrombocythemla
  • Factor II
  • Factor V
  • Platelet glycoprotein
  • Polycythemia vera

ASJC Scopus subject areas

  • Hematology

Cite this

Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. / Afshar-Kharghan, Vahid; López, José A.; Gray, Leigh A.; Padilla, Arnoldo; Borthakur, Gautam; Roberts, Stacy C.; Pruthi, Rajiv K.; Tefferi, Ayalew.

In: Blood Coagulation and Fibrinolysis, Vol. 15, No. 1, 01.2004, p. 21-24.

Research output: Contribution to journalArticle

Afshar-Kharghan, Vahid ; López, José A. ; Gray, Leigh A. ; Padilla, Arnoldo ; Borthakur, Gautam ; Roberts, Stacy C. ; Pruthi, Rajiv K. ; Tefferi, Ayalew. / Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. In: Blood Coagulation and Fibrinolysis. 2004 ; Vol. 15, No. 1. pp. 21-24.
@article{02a24946472d4950af6819e294a2ed1d,
title = "Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia",
abstract = "Patients with polycythemia vera and essential thrombocythemia are at risk for thrombotic and bleeding complications. Currently, no diagnostic test can predict thrombohemorrhagic complications. In a prospective study of 86 patients with polycythemia vera (43 patients) or essential thrombocythemia (43 patients), we examined the possible role of polymorphisms of platelet adhesion receptors [glycoprotein (GP) Ibα, GPIa, GPIIIa) and clotting factor II (prothrombin's G20210A mutation) and clotting factor V (Leiden mutation) in determining the risk of thrombotic or bleeding complications. Except for an association between vasomotor symptoms and prothrombin mutation (P < 0.001), no significant correlation between polymorphism of clotting factors and thrombohemorrhagic complications was identified. When the entire patient cohort was considered, the polymorphisms of platelet adhesion receptors were not associated with the risk for thrombotic or bleeding complications. However, among patients with polycythemia vera, the presence of the PIA2 allele of GPIIIa was associated with an increased risk of arterial thrombosis. In view of previous studies linking the presence of the PIA2 allele of GPIIIa to a higher risk for coronary artery thrombosis, our data have physiologic relevance. However, they need to be confirmed in a larger study.",
keywords = "Essential thrombocythemla, Factor II, Factor V, Platelet glycoprotein, Polycythemia vera",
author = "Vahid Afshar-Kharghan and L{\'o}pez, {Jos{\'e} A.} and Gray, {Leigh A.} and Arnoldo Padilla and Gautam Borthakur and Roberts, {Stacy C.} and Pruthi, {Rajiv K.} and Ayalew Tefferi",
year = "2004",
month = "1",
doi = "10.1097/00001721-200401000-00004",
language = "English (US)",
volume = "15",
pages = "21--24",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia

AU - Afshar-Kharghan, Vahid

AU - López, José A.

AU - Gray, Leigh A.

AU - Padilla, Arnoldo

AU - Borthakur, Gautam

AU - Roberts, Stacy C.

AU - Pruthi, Rajiv K.

AU - Tefferi, Ayalew

PY - 2004/1

Y1 - 2004/1

N2 - Patients with polycythemia vera and essential thrombocythemia are at risk for thrombotic and bleeding complications. Currently, no diagnostic test can predict thrombohemorrhagic complications. In a prospective study of 86 patients with polycythemia vera (43 patients) or essential thrombocythemia (43 patients), we examined the possible role of polymorphisms of platelet adhesion receptors [glycoprotein (GP) Ibα, GPIa, GPIIIa) and clotting factor II (prothrombin's G20210A mutation) and clotting factor V (Leiden mutation) in determining the risk of thrombotic or bleeding complications. Except for an association between vasomotor symptoms and prothrombin mutation (P < 0.001), no significant correlation between polymorphism of clotting factors and thrombohemorrhagic complications was identified. When the entire patient cohort was considered, the polymorphisms of platelet adhesion receptors were not associated with the risk for thrombotic or bleeding complications. However, among patients with polycythemia vera, the presence of the PIA2 allele of GPIIIa was associated with an increased risk of arterial thrombosis. In view of previous studies linking the presence of the PIA2 allele of GPIIIa to a higher risk for coronary artery thrombosis, our data have physiologic relevance. However, they need to be confirmed in a larger study.

AB - Patients with polycythemia vera and essential thrombocythemia are at risk for thrombotic and bleeding complications. Currently, no diagnostic test can predict thrombohemorrhagic complications. In a prospective study of 86 patients with polycythemia vera (43 patients) or essential thrombocythemia (43 patients), we examined the possible role of polymorphisms of platelet adhesion receptors [glycoprotein (GP) Ibα, GPIa, GPIIIa) and clotting factor II (prothrombin's G20210A mutation) and clotting factor V (Leiden mutation) in determining the risk of thrombotic or bleeding complications. Except for an association between vasomotor symptoms and prothrombin mutation (P < 0.001), no significant correlation between polymorphism of clotting factors and thrombohemorrhagic complications was identified. When the entire patient cohort was considered, the polymorphisms of platelet adhesion receptors were not associated with the risk for thrombotic or bleeding complications. However, among patients with polycythemia vera, the presence of the PIA2 allele of GPIIIa was associated with an increased risk of arterial thrombosis. In view of previous studies linking the presence of the PIA2 allele of GPIIIa to a higher risk for coronary artery thrombosis, our data have physiologic relevance. However, they need to be confirmed in a larger study.

KW - Essential thrombocythemla

KW - Factor II

KW - Factor V

KW - Platelet glycoprotein

KW - Polycythemia vera

UR - http://www.scopus.com/inward/record.url?scp=2042477375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2042477375&partnerID=8YFLogxK

U2 - 10.1097/00001721-200401000-00004

DO - 10.1097/00001721-200401000-00004

M3 - Article

C2 - 15166939

AN - SCOPUS:2042477375

VL - 15

SP - 21

EP - 24

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 1

ER -